A
Achieve Life Sciences, Inc. (ACHV)
NCM – Real Time Price. Currency in USD
6.02
+0.32 (5.61%)
At close: Jun 26, 2026, 4:00 PM EDT
5.94
-0.08 (-1.33%)
After-hours: Jun 26, 2026, 7:56 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
6.02
+0.32 (5.61%)
At close: Jun 26, 2026, 4:00 PM EDT
5.94
-0.08 (-1.33%)
After-hours: Jun 26, 2026, 7:56 PM EDT
Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms. It has license and supply agreements with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washington.
| Name | Position |
|---|---|
| Dr. Andrew D. Goldberg M.D. | CEO, President & Director |
| Mr. Erik Atkisson | Chief Legal Officer |
| Mr. Jerry Wan | VP of Finance & Principal Accounting Officer |
| Mr. Mark Zappia | Senior Vice President of Commercial |
| Mr. Mark K. Oki CPA | Chief Financial Officer |
| Ms. Nicole P. Jones | Vice President of Strategic Communications & Stakeholder Relations |
| Date | Type | Document |
|---|---|---|
| 2026-06-08 | DEF 14A | achv-20260604.htm |
| 2026-06-08 | ARS | proxy_2026_ars.pdf |
| 2026-06-02 | 8-K | achv-20260529.htm |
| 2026-05-29 | PRE 14A | achv-20260529.htm |
| 2026-05-12 | S-8 | achv-20260512.htm |
| 2026-05-12 | S-3 | achv-20260512.htm |
| 2026-05-12 | 8-K | d854692d8k.htm |
| 2026-04-30 | 10-K/A | achv-20251231.htm |
| 2026-04-16 | S-8 | achv-20260416.htm |
| 2026-04-16 | 8-K | achv-20260415.htm |